Prednisone (PDN)/Sirolimus (SRL) Compared to PDN/SRL/Calcineurin Inhibitor (CNI) as Treatment for Chronic Graft-Versus-Host-Disease (cGVHD): A Randomized.

Slides:

Advertisements

Similar presentations

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis.

Advertisements

Topical Ruxolitinib Protects LGR5+ Stem Cells in the Hair Follicle and Ameliorates Skin Graft-Versus-Host Disease Shuichiro Takahashi, MD, Daigo Hashimoto,

Stephanie J. Lee, Loretta A. Williams

Biology of Blood and Marrow Transplantation

Center for International Blood and Marrow Transplant Research Chronic Graft-versus- Host Disease Risk Score Predicts Mortality in an Independent Validation.

Clinical Evaluation of Oral Chronic Graft-Versus-Host Disease

Randomized, Double-Blind, Placebo-Controlled Trial of Soluble Tumor Necrosis Factor Receptor: Enbrel (Etanercept) for the Treatment of Idiopathic Pneumonia.

FDG-PET Interpreted By Deauville Criteria Prior to Allogeneic Transplantation Predicts Outcomes in Patients with Relapsed or Refractory Hodgkin Lymphoma

Increasing Incidence of Chronic Graft-versus-Host Disease in Allogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant.

Impact of Pre-Transplant Minimal Residual Disease in Patients with AML Undergoing Myeloablative Cord Blood Transplantation Filippo Milano, MD, PhD, Brent.

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis.

B Cells in Chronic Graft-versus-Host Disease

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2014 Biomarker.

Late Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation Aazim K. Omer, Daniel J. Weisdorf, Aleksandr Lazaryan,

Implementation of Post-Transplant Assessment Tools for Improved Accuracy of Graft- Versus-Host Disease Reporting Madhu Ragupathi, Jaskiran Kaur, Luda.

Oral Manifestations Compatible with Chronic Graft-versus-Host Disease in Patients with Fanconi Anemia Laura Grein Cavalcanti, Renata L. Fuentes Araújo,

Sonidegib (LDE-225), a Sonic Hedgehog Pathway Inhibitor, for the Treatment of Steroid- Refractory Chronic Graft-Versus-Host Disease Zachariah DeFilipp,

Encouraging Results of a Phase II Trial of Inhaled Fluticasone Propionate, Azithromycin, and Montelukast (FAM) May Maintain Lung Function in Bronchiolitis.

Peripheral Blood Grafts from Unrelated Donors Are Associated with Increased Acute and Chronic Graft-versus-Host Disease without Improved Survival Mary.

Stephanie J. Lee, Loretta A. Williams

Chronic graft-versus-host disease

Impact of Age on Quality of Life, Functional Status, and Survival in Patients with Chronic Graft-versus-Host Disease Areej El-Jawahri, Joseph Pidala,

Clinical Benefit of Response in Chronic Graft-versus-Host Disease

Comparison of Short-Term Response and Long-Term Outcomes after Initial Systemic Treatment of Chronic Graft-Versus-Host Disease Paul J. Martin, Barry.

Recent Decrease in Acute Graft-versus-Host Disease in Children with Leukemia Receiving Unrelated Donor Bone Marrow Transplants Stella M. Davies, Dan.

More Infections with Transplantation of Bone Marrow, Versus Peripheral-Blood Stem Cells, from Unrelated Donors Jo-Anne H. Young, MD, Brent R. Logan,

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. The 2014 Ancillary.

Pulse Cyclophosphamide for Steroid-Refractory Chronic Graft-Versus-Host Disease Nelson J. Chao, MD, MBA, Yevgeniya Gora Foster, MD, Krista Rowe, RN, MSN,

Lymphocyte Phenotype during Therapy for Acute Graft-versus-Host Disease: A Brief Report from BMT-CTN 0302 Javier Bolaños-Meade, Juan Wu, Brent R. Logan,

Higher Dose of Mycophenolate Mofetil Reduces Acute Graft-versus-Host Disease in Reduced-Intensity Conditioning Double Umbilical Cord Blood Transplantation

Should Methotrexate plus Calcineurin Inhibitors Be Considered Standard of Care for Prophylaxis of acute Graft-versus-Host Disease? Rainer Storb, Joseph.

Multicenter Biologic Assignment Trial Comparing Reduced-Intensity Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive.

Oral Chronic Graft-versus-Host Disease Scoring Using the NIH Consensus Criteria Nathaniel S. Treister, Kristen Stevenson, MS, Haesook Kim, Sook-Bin Woo,

Measuring Therapeutic Response in Chronic Graft-versus-Host Disease

A Novel Strategy in Managing Post-Liver Transplant Acute Graft-Versus-Host-Disease: The New Era (T)Rojan Horse Zeyad Kanaan, MD, William Tse, MD, FACP

Reprint of: B Cells in Chronic Graft-versus-Host Disease

Betty K. Hamilton, Lisa Rybicki, Sally Arai, Mukta Arora, Corey S

GVHD Prophylaxis with Post-Transplant High Dose Cyclophosphamide: Impact on Engraftment, Treatment-Related Mortality and Resource Utilization Nasheed.

Biology of Blood and Marrow Transplantation

Frederick R. Appelbaum, Claudio Anasetti, Joseph H

Graft-versus-Host Disease Induced Graft-versus-Leukemia Effect: Greater Impact on Relapse and Disease-Free Survival after Reduced Intensity Conditioning

Similar Invasive Fungal Infection Rates and Survival after Allogeneic Hematopoietic Cell Transplantation with Umbilical Cord Blood and Bone Marrow or.

A Phase III Study of Infliximab and Corticosteroids for the Initial Treatment of Acute Graft-versus-Host Disease Daniel R. Couriel, Rima Saliba, Marcos.

Ancillary Therapy and Supportive Care of Chronic Graft-versus-Host Disease: National Institutes of Health Consensus Development Project on Criteria for.

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. The 2014 Clinical.

Biology of Blood and Marrow Transplantation

Myeloablative Transplantation using either Cord Blood or Bone Marrow leads to Immune Recovery, High Long-Term Donor Chimerism and Excellent Survival in.

Analysis of Gastrointestinal and Hepatic Chronic Grant-versus-Host Disease Manifestations on Major Outcomes: A Chronic Grant-versus-Host Disease Consortium.

Exercise and Stress Management Training Prior to Hematopoietic Cell Transplantation: Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0902

Amphiregulin Modifies the Minnesota Acute Graft-Versus-Host Disease Risk Score: Results from BMT CTN Acute Gvhd Therapy Trials Shernan G. Holtan, Todd.

Mohammad Alhyari, M. D. , Aymen Bukannan, M. D. , Kimberly Brown, M. D

Low-Dose IL-2 Therapy Preferentially Improves Diversity of the Regulatory T Cell Repertoire in Patients with Refractory Chronic Graft-Versus-Host Disease

Guidance for Developing Phase II Cell Therapy Trial Proposals for Consideration by the Blood and Marrow Transplant Clinical Trials Network Edwin M. Horwitz,

Chronic Graft-Versus-Host Disease (cGVHD) following Unrelated Donor Hematopoietic Stem Cell Transplantation (HSCT): Higher Response Rate In Recipients.

Content Validity of the Lee Chronic Graft-versus-Host Disease Symptom Scale as Assessed by Cognitive Interviews Emily C. Merkel, Sandra A. Mitchell,

Redesigning Care to Lower Episode Costs in Bone Marrow Transplantation

John E. Levine, Sophie Paczesny, Stefanie Sarantopoulos

Biology of Blood and Marrow Transplantation

Unrelated Donor Hematopoietic Cell Transplantation: Factors Associated with a Better HLA Match Jason Dehn, Mukta Arora, Stephen Spellman, Michelle Setterholm,

A Refined Risk Score for Acute Graft-versus-Host Disease that Predicts Response to Initial Therapy, Survival, and Transplant-Related Mortality Margaret.

Calcinuerin-Inhibitor (CI) Free Graft-Versus-Host Disease (GvHD) Prophylaxis: Its Effects on Magnesium, Renal Function, and the Cost of Care Marlee Muilenburg,

Preengraftment Syndrome after Unrelated Cord Blood Transplant Is a Strong Predictor of Acute and Chronic Graft-versus-Host Disease Haydar Frangoul, Li.

Reduced Intensity Versus Myeloablative Conditioning Allogeneic HCT for Relapsed/Refractory Lymphoma: Applying Refined Disease Risk Index (DRI) to Improve.

Combination Therapy for Graft-versus-Host Disease Prophylaxis with Etanercept and Extracorporeal Photopheresis: Results of a Phase II Clinical Trial

Reduced-Intensity Conditioning for Unrelated Donor Progenitor Cell Transplantation: Long-Term Follow-Up of the First 285 Reported to the National Marrow.

Pulmonary Symptoms Measured by the National Institutes of Health Lung Score Predict Overall Survival, Nonrelapse Mortality, and Patient-Reported Outcomes.

Biology of Blood and Marrow Transplantation

Mary Eapen Biology of Blood and Marrow Transplantation

Graft-versus-Host Disease: State of the Science

Sirolimus and Mycophenolate Mofetil as Calcineurin Inhibitor–Free Graft-versus-Host Disease Prophylaxis for Reduced-Intensity Conditioning Umbilical Cord.

Presentation transcript:

Prednisone (PDN)/Sirolimus (SRL) Compared to PDN/SRL/Calcineurin Inhibitor (CNI) as Treatment for Chronic Graft-Versus-Host-Disease (cGVHD): A Randomized Phase II Study from the Blood and Marrow Transplant Clinical Trials Network Paul A. Carpenter, MD, Brent R. Logan, PhD, Stephanie J. Lee, MD, MPH, Daniel J. Weisdorf, MD, Laura Johnston, MD, Luciano J. Costa, MD, PhD, Carrie L. Kitko, MD, Javier Bolaños-Meade, MD, Amin M. Alousi, MD, Mary M. Horowitz, MD, MS, Sunil Abhyankar, MD, Edmund K. Waller, MD, PhD, Adam Mendizabal, PhD, Yanli Wang, Aleksandr Lazaryan, MD MPH PhD, Shelly L. Carter, ScD, Eneida R. Nemecek, MD, Steven Z. Pavletic, MD, Corey S. Cutler, MD, MPH, Mukta Arora, MD, MS Biology of Blood and Marrow Transplantation Volume 22, Issue 3, Pages S50-S52 (March 2016) DOI: 10.1016/j.bbmt.2015.11.336 Copyright © 2016 Terms and Conditions

Figure 1 Steroid Dose Biology of Blood and Marrow Transplantation 2016 22, S50-S52DOI: (10.1016/j.bbmt.2015.11.336) Copyright © 2016 Terms and Conditions

Figure 2A Failure-Free Survival for PDN/SRL/CN1 Arm Biology of Blood and Marrow Transplantation 2016 22, S50-S52DOI: (10.1016/j.bbmt.2015.11.336) Copyright © 2016 Terms and Conditions

Figure 2B Failure-Free Survival for PDN/SRL Arm Biology of Blood and Marrow Transplantation 2016 22, S50-S52DOI: (10.1016/j.bbmt.2015.11.336) Copyright © 2016 Terms and Conditions